Rezolute, Inc. (RZLT) - Q2 2026 Filing Summary
Business Context and Reporting Period
This summary covers Rezolute, Inc.'s Form 10-Q for the quarterly and six-month periods ended December 31, 2025. Rezolute is a late-stage rare disease company focused on developing biologics for hyperinsulinism (HI). The company's primary asset is ersodetug, currently in Phase 3 trials for congenital HI (sunRIZE study) and tumor HI (upLIFT study). The company operates as a single reportable segment and is classified as a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Dec 31, 2025 | Six Months Ended Dec 31, 2025 | Balance Sheet (Dec 31, 2025) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(22,774) | $(40,924) | N/A |
| Operating Expenses | $24,221 | $44,038 | N/A |
| Research & Development | $14,348 | $27,497 | N/A |
| General & Administrative | $9,873 | $16,541 | N/A |
| Cash & Cash Equivalents | N/A | N/A | $11,944 |
| Marketable Debt Securities | N/A | N/A | $120,994 |
| Total Capital Resources | N/A | N/A | $132,938 |
| Accumulated Deficit | N/A | N/A | $(444,780) |
| Net Cash Used in Operating Activities | N/A | $(37,754) | N/A |
Material Changes vs. Prior Period
- Clinical Trial Outcome: In December 2025, the company announced that the Phase 3 sunRIZE study for congenital HI did not meet its primary or key secondary endpoints. The company attributes this to a pronounced placebo effect and confounding behaviors in patient-monitored glucose data.
- Workforce Reduction: Following the sunRIZE results, management approved a reduction of 29 employees on December 15, 2025. This resulted in a one-time severance expense of approximately $1.5 million (included in Q2 operating expenses).
- Expense Increases:
- R&D Expenses: Increased by 14% ($1.7M) for the quarter and 8% ($2.1M) for the six months compared to the prior year periods. Increases were driven by higher compensation, severance costs, and clinical trial activities, partially offset by lower manufacturing costs.
- G&A Expenses: Increased significantly by 122% ($5.4M) for the quarter and 91% ($7.9M) for the six months. This was driven by business development activities, increased compensation, and severance costs.
- Liquidity Position: Cash and cash equivalents decreased from $94.1 million (June 30, 2025) to $11.9 million (December 31, 2025). However, total capital resources (cash + marketable securities) remain at $132.9 million due to significant investment activity.
Guidance, Outlook, and Risks
- Regulatory Path Forward: The company plans to meet with the FDA in Q1 2026 to discuss the sunRIZE results and potential next steps for the congenital HI indication. The FDA may require additional clinical studies.
- Tumor HI Program: The company remains focused on the Phase 3 upLIFT study for tumor HI, which utilizes a modified single-arm, open-label design approved by the FDA. Topline results are anticipated in the second half of calendar 2026.
- Liquidity Outlook: Management believes current capital resources ($132.9 million) are sufficient to fund operations and clinical trials for at least 12 months from the filing date. However, additional financing will be required for long-term needs.
- Risks and Contingencies:
- Legal Proceedings: Law firms have initiated investigations into potential securities law violations following the sunRIZE trial results and stock price decline. No lawsuits have been filed as of the filing date.
- Milestone Payments: The company has significant future contingent liabilities, including a $25.0 million regulatory milestone to XOMA upon approval of ersodetug and up to $25.0 million in clinical/regulatory milestones to ActiveSite.
- Going Concern: While currently funded for 12 months, the company has incurred cumulative losses of $444.8 million and has no revenue, creating a dependency on future financing.
Key Facts for Investor Verification
- sunRIZE Trial Failure: Verify the specific details of the FDA meeting scheduled for Q1 2026 and the company's proposed path forward for the congenital HI indication.
- upLIFT Study Progress: Monitor enrollment status and any updates regarding the Phase 3 tumor HI study, which is now the primary driver for potential approval.
- Cash Burn Rate: Confirm the sustainability of the current cash position ($132.9M) against the increased operating expenses and the potential need for additional capital raises.
- Legal Exposure: Track the status of the securities law investigations mentioned in the Risk Factors section to assess potential litigation costs.
- Severance Impact: Note that the $1.5 million severance liability was paid in full in January 2026, removing this specific cash outflow from future quarters.